Estats Units - anglès - NLM (National Library of Medicine)

bryant ranch prepack - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules (see microbiology ). flucytosine capsules should not be used in patients with a known hypersensitivity to the drug.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cytarabine, quantity: 5000 mg - injection, solution - excipient ingredients: trometamol; water for injections; macrogol 400 - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cytarabine, quantity: 40 mg - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; sodium chloride - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cytarabine, quantity: 500 mg - injection, solution - excipient ingredients: water for injections; macrogol 400; trometamol - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cytarabine, quantity: 2000 mg - injection, solution - excipient ingredients: water for injections; macrogol 400; trometamol - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cytarabine, quantity: 4000 mg - injection, solution - excipient ingredients: water for injections; macrogol 400; trometamol - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

Estats Units - anglès - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules usp is indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules usp should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules usp (see microbiology). flucytosine capsules, usp is contraindicated in patients with a known hypersensitivity to the drug. flucytosine capsules, usp is contraindicated in patients with known complete dihydropyrimidine dehydrogenase (dpd) enzyme deficiency (see warnings).

Estats Units - anglès - NLM (National Library of Medicine)

novel laboratories, inc. - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules usp is indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules usp should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules usp (see microbiology). flucytosine capsules, usp is contraindicated in patients with a known hypersensitivity to the drug. flucytosine capsules, usp is contraindicated in patients with known complete dihydropyrimidine dehydrogenase (dpd) enzyme deficiency (see warnings).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cytarabine -

Estats Units - anglès - NLM (National Library of Medicine)

hospira, inc. - cytarabine (unii: 04079a1rdz) (cytarabine - unii:04079a1rdz) - cytarabine injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. it has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. intrathecal administration of cytarabine injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia. cytarabine injection is contraindicated in those patients who are hypersensitive to the drug.